1 / 49

Legend for Supplementary Fig. 1-60

Legend for Supplementary Fig. 1-60

sdonnelly
Download Presentation

Legend for Supplementary Fig. 1-60

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Legend for Supplementary Fig. 1-60 MacRM-001 (2 mL each) for use as a calibrator and the one set of sera for commutability assessment (0.5 mL each of 150 sera (=30 patients’ sera in 5 groups)) were sent to 28 laboratories using temperature monitors that confirmed receipt in the frozen state. In the individual laboratories, the patient sera and MacRM-001 were measured according to their own routine methods using duplicate automated analyses. Using these patients’ sera, we examined the relationships between patient sera (●), MacRM-001 (□) and the CRMs (△) used for traceability of the MacRM target values for all combinations of assay methods and assay platforms (shown in Supplementary Tables 2, 4, 5 and ref. 16) of the 30 analytes in 28 laboratories.

  2. Suppl. fig. 31a. Assessment of MacRM commutability by twin plot analysis (Glucose) : Patient sera (n=30) : NIST SRM917c : MacRM-000

  3. Suppl. fig. 31b. Assessment of MacRM commutability by twin plot analysis (Glucose) : Patient sera (n=30) : NIST SRM917c : MacRM-000

  4. Suppl. fig. 32a. Assessment of MacRM commutability by twin plot analysis (UA) : Patient sera (n=30) : NIST SRM913b : MacRM-000

  5. Suppl. fig. 32b. Assessment of MacRM commutability by twin plot analysis (UA) : Patient sera (n=30) : NIST SRM913b : MacRM-000

  6. Suppl. fig. 33a. Assessment of MacRM commutability by twin plot analysis (UN) : Patient sera (n=27) : NIST SRM912a : MacRM-000

  7. Suppl. fig. 33b. Assessment of MacRM commutability by twin plot analysis (UN) : Patient sera (n=27) : NIST SRM912a : MacRM-000

  8. Suppl. fig. 33c. Assessment of MacRM commutability by twin plot analysis (UN) : Patient sera (n=27) : NIST SRM912a : MacRM-000

  9. Suppl. fig. 34a. Assessment of MacRM commutability by twin plot analysis (Cre) : Patient sera (n=30) : NIST SRM914a : MacRM-000

  10. Suppl. fig. 34b. Assessment of MacRM commutability by twin plot analysis (Cre) : Patient sera (n=30) : NIST SRM914a : MacRM-000

  11. Suppl. fig. 35. Assessment of MacRM commutability by twin plot analysis (TB) : Patient sera (n=30) : MacRM-000

  12. Suppl. fig. 36. Assessment of MacRM commutability by twin plot analysis (Fe) : Patient sera (n=30) : NIST SRM937 : MacRM-000

  13. Suppl. fig. 37. Assessment of MacRM commutability by twin plot analysis (Na) : Patient sera (n=30) : JCCRM 111-6 : MacRM-000

  14. Suppl. fig. 38. Assessment of MacRM commutability by twin plot analysis (K) : Patient sera (n=30) : JCCRM 111-6 : MacRM-000

  15. Suppl. fig. 39. Assessment of MacRM commutability by twin plot analysis (Cl) : Patient sera (n=30) : JCCRM 111-6 : MacRM-000

  16. Suppl. fig. 40a. Assessment of MacRM commutability by twin plot analysis (Ca) : Patient sera (n=30) : NIST SRM915b : MacRM-000

  17. Suppl. fig. 40b. Assessment of MacRM commutability by twin plot analysis (Ca) : Patient sera (n=30) : NIST SRM915b : MacRM-000

  18. Suppl. fig. 41a. Assessment of MacRM commutability by twin plot analysis (IP) : Patient sera (n=30) : NIST SRM200b : MacRM-000

  19. Suppl. fig. 41b. Assessment of MacRM commutability by twin plot analysis (IP) : Patient sera (n=30) : NIST SRM200b : MacRM-000

  20. Suppl. fig. 42a. Assessment of MacRM commutability by twin plot analysis (Mg) : Patient sera (n=30) : NIST SRM929a : MacRM-000

  21. Suppl. fig. 42b. Assessment of MacRM commutability by twin plot analysis (Mg) : Patient sera (n=30) : NIST SRM929a : MacRM-000

  22. Suppl. fig. 43a. Assessment of MacRM commutability by twin plot analysis (AST) : Patient sera (n=29) : JCCLS CRM-001c : MacRM-000

  23. Suppl. fig. 43b. Assessment of MacRM commutability by twin plot analysis (AST) : Patient sera (n=29) : JCCLS CRM-001c : MacRM-000

  24. Suppl. fig. 44a. Assessment of MacRM commutability by twin plot analysis (ALT) : Patient sera (n=28) : JCCLS CRM-001c : MacRM-000

  25. Suppl. fig. 44b. Assessment of MacRM commutability by twin plot analysis (ALT) : Patient sera (n=28) : JCCLS CRM-001c : MacRM-000

  26. Suppl. fig. 45a. Assessment of MacRM commutability by twin plot analysis (ALP) : Patient sera (n=27) : JCCLS CRM-001c : MacRM-000

  27. Suppl. fig. 45b. Assessment of MacRM commutability by twin plot analysis (ALP) : Patient sera (n=27) : JCCLS CRM-001c : MacRM-000

  28. Suppl. fig. 46a. Assessment of MacRM commutability by twin plot analysis (LD) : Patient sera (n=30) : JCCLS CRM-001c : MacRM-000

  29. Suppl. fig. 46b. Assessment of MacRM commutability by twin plot analysis (LD) : Patient sera (n=30) : JCCLS CRM-001c : MacRM-000

  30. Suppl. fig. 47a. Assessment of MacRM commutability by twin plot analysis (AMY) : Patient sera (n=30) : JCCLS CRM-001c : MacRM-000

  31. Suppl. fig. 47b. Assessment of MacRM commutability by twin plot analysis (AMY) : Patient sera (n=30) : JCCLS CRM-001c : MacRM-000

  32. Suppl. fig. 48a. Assessment of MacRM commutability by twin plot analysis (CK) : Patient sera (n=28) : JCCLS CRM-001c : MacRM-000

  33. Suppl. fig. 48b. Assessment of MacRM commutability by twin plot analysis (CK) : Patient sera (n=28) : JCCLS CRM-001c : MacRM-000

  34. Suppl. fig. 49a. Assessment of MacRM commutability by twin plot analysis (GGT) : Patient sera (n=25) : JCCLS CRM-001c : MacRM-000

  35. Suppl. fig. 49b. Assessment of MacRM commutability by twin plot analysis (GGT) : Patient sera (n=25) : JCCLS CRM-001c : MacRM-000

  36. Suppl. fig. 50. Assessment of MacRM commutability by twin plot analysis (ChE) : Patient sera (n=30) : JCCLS CRM-002c : MacRM-000

  37. Suppl. fig. 51. Assessment of MacRM commutability by twin plot analysis (TC) : Patient sera (n=30) : NIST SRM1951c : MacRM-000

  38. Suppl. fig. 52. Assessment of MacRM commutability by twin plot analysis (TG) : Patient sera (n=25) : NIST SRM1951c : MacRM-000

  39. Suppl. fig. 53. Assessment of MacRM commutability by twin plot analysis (HDL-C) : Patient sera (n=29) : NIST SRM1951c : MacRM-000

  40. Suppl. fig. 54. Assessment of MacRM commutability by twin plot analysis (LDL-C) : Patient sera (n=29) : NIST SRM1951c : MacRM-000

  41. Suppl. fig. 55a. Assessment of MacRM commutability by twin plot analysis (CRP) : Patient sera (n=28) : IRMM ERM-DA474 : MacRM-000

  42. Suppl. fig. 55b. Assessment of MacRM commutability by twin plot analysis (CRP) : Patient sera (n=28) : IRMM ERM-DA474 : MacRM-000

  43. Suppl. fig. 56a. Assessment of MacRM commutability by twin plot analysis (Alb) : Patient sera (n=30) : IRMM ERM-DA470k : MacRM-000

  44. Suppl. fig. 56b. Assessment of MacRM commutability by twin plot analysis (Alb) : Patient sera (n=30) : IRMM ERM-DA470k : MacRM-000

  45. Suppl. fig. 57. Assessment of MacRM commutability by twin plot analysis (IgG) : Patient sera (n=30) : IRMM ERM-DA470k : MacRM-000

  46. Suppl. fig. 58. Assessment of MacRM commutability by twin plot analysis (IgA) : Patient sera (n=28) : IRMM ERM-DA470k : MacRM-000

  47. Suppl. fig. 59. Assessment of MacRM commutability by twin plot analysis (IgM) : Patient sera (n=28) : IRMM ERM-DA470k : MacRM-000

  48. Suppl. fig. 60a. Assessment of MacRM commutability by twin plot analysis (TP) : Patient sera (n=28) : MacRM-000

  49. Suppl. fig. 60b. Assessment of MacRM commutability by twin plot analysis (TP) : Patient sera (n=28) : MacRM-000

More Related